What the US credit downgrade means for the economy, your finances

1:44TheU.S.CapitolBuildingisshownonAug.1,2023inWashington.AnnaMoneymaker/GettyImagesAratingagencydow AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin




hotspot

author：fashion    Page View：732
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： Micronoma's microbiome cancer diagnostic approach under fire
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts